Current Clopidogrel News and Events

Current Clopidogrel News and Events, Clopidogrel News Articles.
Sort By: Most Relevant | Most Viewed
Page 1 of 7 | 280 Results
In-stent thrombosis after antiplatelet therapy conversion while awaiting coronary bypass
In a new publication from Cardiovascular Innovations and Applications; DOI https://doi.org/10.15212/CVIA.2019.0589, Nathan Burke, Tawanna Charlton, Hussam Hawamdeh, and Ki Park from the University of Florida College of Medicine, Gainesville, Florida, USA consider a case study of in-stent thrombosis after antiplatelet therapy conversion while awaiting coronary bypass. (2020-11-19)

Ticagrelor was not superior to clopidogrel to reduce heart attack risk during angioplasty
A new study found the rate of heart attack and severe complications before, during or soon after elective surgery to open a blocked artery was similar between patients treated with clopidogrel and those who received the more potent antiplatelet medication ticagrelor. (2020-11-14)

CVIA has just published a new issue, Volume 5 Issue 1
The journal Cardiovascular Innovations and Applications (CVIA) has just published the first issue of Volume 5. Included in the issue is a paper of major importance on Serum Procalcitonin Levels on Admission Predict Death in Severe and Critical COVID-19 Patients in Wuhan, China (2020-10-19)

Study reveals best anti-clotting strategy after heart valve intervention
The POPular TAVI trial has challenged current guideline recommendations on antiplatelet treatment after transcatheter aortic valve implantation (TAVI) in patients not taking oral anticoagulation. The findings are presented in a Hot Line session today at ESC Congress 2020. (2020-08-31)

Cardiology trial shows potential benefit of genetic testing when selecting blood thinners
An international, first-of-its-kind cardiology trial used personalized genetic testing to reduce by 34 per cent the number of serious adverse events following balloon angioplasty, a treatment for the most common form of heart disease. (2020-08-25)

Clinical trial shows potential benefit to anti-platelet therapy
Heart patients who undergo percutaneous coronary intervention (PCI) or stent placement? nonsurgical procedures to improve blood flow to the heart are typically prescribed anti-platelet therapy to avoid blood clots that can lead to a heart attack or stroke. New research from the international TAILOR-PCI trial, the largest pharmacogenetics clinical trial in cardiology, suggests that genetic testing could potentially be a useful tool to help select antiplatelet medication. (2020-08-25)

NSAIDs increase cardiovascular, bleeding risk in Korean heart attack patients
Use of NSAIDs to treat first-time heart attack patients significantly increased the risk for cardiovascular and bleeding events post-heart attack in a nationwide Korean study, published today in the Journal of the American College of Cardiology. (2020-07-27)

Precision medicine guides choice of better drug therapy in severe heart disease
Is personalized medicine cost-effective? Researchers have answered that question for one medical treatment, genotype-guided antiplatelet therapy for acute coronary syndrome patients with PCI. Their study uses pharmacogenomics and economic analysis of real-world clinical data. (2020-05-14)

Prime time for lower extremity artery disease
This article provides an overview of the indications and techniques of lower extremity revascularisation, and an in-depth analysis of the available evidence regarding type and duration of antiplatelet and anticoagulant treatment following endovascular and surgical revascularisation. (2020-05-06)

Genetic testing for antiplatelet therapy post-PCI misses cut in cardiovascular events
An international clinical trial that used genetic testing to guide which antiplatelet medication was given to patients following percutaneous coronary intervention (PCI) did not meet its stated goal for cutting in half the incidence of serious adverse cardiovascular events, such as heart attack and stroke, in the year following the procedure, according to study results presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC). (2020-03-30)

Rivaroxaban reduces risk in symptomatic PAD post-intervention
People with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg (lower extremity revascularization) had a 15% reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC). (2020-03-30)

Clopidogrel atop rivaroxaban and aspirin shows no added benefit for PAD
The results of VOYAGER PAD found that people with peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing lower extremity revascularization -- a procedure to treat blocked arteries in the leg -- had a significant reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone, according to a subgroup analysis from VOYAGER PAD presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC). (2020-03-30)

Antiplatelet drugs increase risk for TAVR patients with atrial fibrillation
Patients with atrial fibrillation who took oral anticoagulants alone after undergoing transcatheter aortic valve replacement (TAVR) had a lower rate of bleeding complications without an increased risk of clotting-related complications compared to patients who took antiplatelet medication in addition to oral anticoagulants, in a trial presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC). (2020-03-30)

Improving cardiovascular health of the most vulnerable
A two-year pilot project led by Rick Stouffer, MD, shows how the cardiovascular health of the most vulnerable patients can be improved with free medications. (2020-01-21)

Study analyzes outcomes of dual antiplatelet therapy after minor stroke or TIA
An analysis of combined patient-level data from two randomized clinical trials  examined outcomes of dual antiplatelet therapy with clopidogrel and aspirin after minor stroke or transient ischemic attack. (2019-08-19)

Aspirin green light for brain bleed stroke patients, study finds
People who suffer a stroke caused by bleeding in the brain -- known as brain haemorrhage -- can take common medicines without raising their risk of another stroke, a major clinical trial has found. Researchers say the findings are reassuring for the thousands of people who take the medicines to reduce their risk of heart attack and another common type of stroke caused by blood clots in the brain. (2019-05-22)

New computer-based predictive tool more accurately forecasts outcomes for respiratory patients
Are electronic health records and computer calculations a better, more accurate way to predict clinical outcomes for patients with chronic obstructive pulmonary disease? According to the results of a new study by researchers at Intermountain Healthcare in Salt Lake City, the answer is yes. (2019-05-20)

Apixaban plus P2Y12 inhibitor and no aspirin safest for patients with both AFib and ACS
Patients at high risk for heart attacks, strokes and blood clots who were treated with a novel blood thinner (apixaban) and an antiplatelet drug such as clopidogrel had a significantly lower risk of bleeding and being hospitalized compared with patients who received an older blood-thinning medication such as warfarin, according to research presented at the American College of Cardiology's 68th Annual Scientific Session. (2019-03-18)

Stopping DAPT after one-month improved outcomes in stent patients
Patients who stopped taking aspirin one month after receiving a stent in the heart's arteries but continued taking the P2Y12 inhibitor clopidogrel fared significantly better after one year compared with those who followed the standard practice of continuing both medications, according to research presented at the American College of Cardiology's 68th Annual Scientific Session. (2019-03-18)

Stopping aspirin three months after stenting does not increase risk of death
Patients who stopped taking aspirin three months after receiving a stent to open the heart's arteries but continued taking a P2Y12 inhibitor -- clopidogrel, prasugrel or ticagrelor -- did not experience higher rates of death from any cause, heart attack or stroke after a year compared with those receiving standard therapy, according to research presented at the American College of Cardiology's 68th Annual Scientific Session. Furthermore, patients who stopped taking aspirin after three months had a significantly lower rate of bleeding. (2019-03-18)

Ticagrelor is as safe and effective as clopidogrel after heart attack
Patients given clot busters to treat a heart attack fared equally well if they were given the standard blood thinning medication clopidogrel versus the newer, more potent drug ticagrelor, according to research presented at the American College of Cardiology's 68th Annual Scientific Session. (2019-03-18)

Cilostazol-combo antiplatelet therapy reduced risk for recurrent stroke
The long-term combination of cilostazol with aspirin or clopidogrel resulted in fewer recurrent strokes than with aspirin or clopidogrel alone in high-risk patients. (2019-02-06)

Researchers find antidepressants significantly raise risk of GI, intracranial bleeding
Nearly 13 percent of Americans 12 years and older take an antidepressant, and SSRIs are among the most frequently prescribed because they are relatively low-cost, effective and safe. However, patients taking these drugs are 40 percent more likely to develop severe gastrointestinal bleeding, particularly when they also use common over-the-counter pain relievers. (2019-01-30)

Modern antiplatelet therapy: When is clopidogrel the right choice?
In the current issue of Cardiovascular Innovations and Applications (Volume3, Number 2, 2018, pp. 149-162(14); DOI: 10.15212/CVIA.2017.0049 Punag Divanji and Kendrick Shunk from the University of California San Francisco and The San Francisco Veteran Affairs Hospital, San Francisco, Calif., USA consider when clopidogrel is the right choice in modern antiplatelet therapy. (2018-09-10)

CVIA special issue on special issue on current issues in cath labs
The journal Cardiovascular Innovations and Applications (CVIA) has just published a new issue, Volume 3 Issue 2. This is a Special Issue on Current Issues in Cath Labs with Guest Editors Anthony A. Bavry of the University of Florida Medical School and Deepak L. Bhatt of Harvard Medical School. This issue brings together papers from leading cardiologists from the United States, China and Europe. (2018-08-29)

International study suggests combination therapy may prevent stroke in certain people
Results from an international clinical trial of more than 4880 participants, published in the New England Journal of Medicine, show that combining clopidogrel and aspirin following a small stroke or experiencing minor stroke symptoms decreases risk of a new stroke, heart attack or other ischemic event within 90 days. The combination therapy was also associated with an increase in major bleeding, although many of those episodes were non-fatal and did not occur in the brain. (2018-05-17)

Stroke prevention drug combo shows promise, study says
If you've had a minor stroke or a transient ischemic stroke (TIA), taking the clot-preventing drug clopidogrel along with aspirin may lower your risk of having a major stroke within the next 90 days, according to new research published in The New England Journal of Medicine. (2018-05-16)

Genetic test may improve post-stent treatment, outcome
A test for specific genetic mutations successfully informed blood-thinner treatment selection following stent placement to open clogged blood vessels, leading to significantly fewer complications. Genetic testing identified patients with specific mutations that render the widely used blood thinner clopidogrel ineffective. Patients with the genetic mutations who received alternative medications were much less likely to die or have a heart attack, stroke or other complications than patients with the mutations who received clopidogrel. (2018-04-03)

Patients do as well on generic antiplatelet drugs as more expensive brand-name product
Patients who took the generic version of the anti-platelet drug clopidogrel after hospitalization for a heart attack or heart-related chest pain had roughly the same odds of death or recurrent heart attack than those who took the brand-name product Plavix®. This indicates that, in real-world use, patients do just as well with generic clopidogrel as with the far-costlier Plavix®. (2018-03-13)

Eliminating cost barriers helps heart patients comply with drug regimens
Doctors often cite the high price of a prescription drug as a reason they don't prescribe it, while patients similarly say that cost is a main reason they quit taking a drug. Removing this financial barrier might increase the use of evidence-based therapies, improve patient adherence to those medications, and potentially save lives. (2018-03-11)

Personalized approach to selecting antiplatelet drugs improves outcomes
Patients with acute coronary syndrome experienced a substantially lower rate of heart attack, stroke, death from cardiovascular causes and major bleeding at 12 months if genetic information was used to inform the selection of their antiplatelet medication in a study presented at the American College of Cardiology's 67th Annual Scientific Session. (2018-03-11)

Ticagrelor has comparable safety to clopidogrel after heart attack
Among people younger than 75 years who were given clot busters to treat a heart attack, taking the more potent blood thinner ticagrelor did not increase the risk of major bleeding (the primary endpoint) compared with the standard blood thinner clopidogrel, in a trial being presented at the American College of Cardiology's 67th Annual Scientific Session. (2018-03-11)

Reducing co-payments improves patient, physician adherence to guideline-recommended treatment post-MI
When patients who had a heart attack were given vouchers to cover their co-payments for medication to prevent a recurrence, physicians were more likely to prescribe a more effective, branded drug and patients were more likely to continue taking the medication for a full year as recommended in treatment guidelines, researchers reported at the American College of Cardiology's 67th Annual Scientific Session. (2018-03-11)

Precision medicine: Access to real-time genetic testing data impacts prescriber behavior following minimally invasive stent procedure
Today, in a late-breaking featured clinical research session at the American College of Cardiology Scientific Sessions 2018, researchers from Penn Medicine present first-of-its-kind data on the impact of real-time CYP2C19 genotype results when prescribing antiplatelet drugs in the clinic. (2018-03-10)

Acute coronary syndromes -- Did prasugrel & ticagrelor offer same benefits as clopidogrel?
In patients presenting with acute coronary syndromes (ACS) either with or without ST-segment elevation MI (STEMI and NSTEMI), dual antiplatelet therapy (DAPT) is recommended for at least 1 year independently of whether revascularization is performed. (2018-02-07)

New study validates clotting risk factors in chronic kidney disease
In late 2017, researchers from Boston University School of Medicine discovered and published a potential treatment target to prevent chronic kidney disease (CKD) patients from developing thrombosis (blood clots) without causing bleeding complications. They found that boosting a regulatory protein named STUB1 decreased the abundance of tissue factor (TF) and prevented blood vessel blockages in experimental models. Now, these same researchers have tested other aspect of this hypothesis in humans with promising results. (2018-01-17)

Registry data examines oral anticoagulant use in women, adverse events after PCI discharge
Data from the American College of Cardiology's National Cardiovascular Data Registry was the source of several published studies in recent months, including a study on predicting 30-day readmission rates for patients undergoing percutaneous coronary intervention and a study that found women were less likely to use oral anticoagulants to treat atrial fibrillation. (2017-10-05)

Rethinking dual antiplatelet guidelines in acute coronary syndrome? (CHANGE-DAPT)
New research presented at ESC Congress today1 suggests that for acute coronary syndrome (ACS) patients who require percutaneous coronary intervention (PCI), treatment according to contemporary guidelines for dual anti-platelet therapy (DAPT) could be less preferable than sticking to older guidelines. (2017-08-29)

When two is better than three: Dual antithrombotic therapy cuts bleeding risk
Clinical trial finds that dabigatran dual therapy after stenting reduced bleeding risk for patients with atrial fibrillation compared with standard triple therapy. (2017-08-27)

New method may help predict risk of bleeding after stroke
A new scoring method may help predict who is at high risk of serious bleeding after a stroke, according to a study published in the Aug. 2, 2017, online issue of Neurology®, the medical journal of the American Academy of Neurology. (2017-08-02)

Page 1 of 7 | 280 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.